Related Experiment Video
Updated: Feb 16, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Increased circulating trimethylamine N-oxide contributes to endothelial dysfunction in a rat model of chronic kidney
Tiejun Li1, Chaojun Gua1, Baogang Wu1
1Department of Cardiology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang 110004, Liaoning, China.
Insights
Elevated trimethylamine-N-oxide (TMAO) in chronic kidney disease (CKD) impairs blood vessel function. Inhibiting TMAO formation in rats with CKD restored endothelial function, suggesting TMAO contributes to cardiovascular disease risk.
Area of Science:
- Nephrology
- Cardiovascular Research
- Microbiome Research
Background:
- Chronic kidney disease (CKD) significantly increases cardiovascular disease (CVD) risk.
- Endothelial dysfunction is a critical early step in CVD pathogenesis and is observed in CKD patients.
- The precise mechanisms driving endothelial dysfunction in CKD remain unclear.
Purpose of the Study:
- To investigate the role of elevated trimethylamine-N-oxide (TMAO) in the development of endothelial dysfunction associated with CKD.
- To test the hypothesis that TMAO contributes to CKD-related cardiovascular complications.
Main Methods:
- Rats underwent 5/6 nephrectomy to induce CKD or a sham operation.
- Animals were treated with 3,3-Dimethyl-1-butanol (DMB), a TMA production inhibitor, or a vehicle control.
- Vascular function, TMAO levels, and molecular markers of oxidative stress and inflammation were assessed.
Main Results:
- CKD rats exhibited significantly elevated circulating TMAO levels compared to controls.
- Endothelium-dependent vasodilation was impaired in CKD rats but normalized with DMB treatment.
- CKD led to decreased endothelial nitric-oxide synthase (eNOS) activity, increased oxidative stress, and elevated inflammation, all reversed by DMB.
Conclusions:
- Elevated TMAO in CKD contributes to endothelial dysfunction.
- TMAO may exacerbate CKD-associated CVD risk by increasing vascular oxidative stress and inflammation, thereby reducing nitric oxide bioavailability.
Abstract:
Chronic kidney disease (CKD) is strongly associated with increased cardiovascular risk. Impaired endothelial function, a key initiating step in the pathogenesis of cardiovascular disease, has been reported in patients with CKD, but the mechanisms responsible for endothelial dysfunction in CKD remain elusive. Emerging evidence reveals that trimethylamine-N-oxide (TMAO), a gut microbiota-generated metabolite, is involved in the pathogenesis of many cardiovascular diseases. Circulating TMAO is elevated in CKD. Here we tested the hypothesis that elevated TMAO plays a contributory role in the pathogenesis of endothelial dysfunction in CKD. Rats underwent 5/6 nephrectomy to induce CKD or sham operation, and were treated with 1.0% 3,3-Dimethyl-1-butanol (DMB, an inhibitor of trimethylamine formation) or vehicle. Eight weeks after nephrectomy and DMB treatment, circulating TMAO levels were markedly elevated in CKD-vehicle rats compared with sham-vehicle rats, but were reduced in CKD-DMB rats. Acetylcholine-induced endothelium-dependent vasodilation was impaired in CKD-vehicle rats compared with sham-vehicle rats as indicated by reduced maximal relaxation (Emax) and decreased area under the curve (AUC). Emax and AUC were both normalized in CKD-DMB rats. No difference in sodium nitroprusside-induced endothelial-independent vasodilation was observed across groups. Molecular studies revealed that endothelial nitric-oxide synthase activity was decreased, while superoxide production and proinflammatory cytokine expression were increased in the aorta of CKD-vehicle rats compared with sham-vehicle rats. Of note, the abnormalities in above molecular parameters were completely restored in CKD-DMB rats. These results suggest that CKD elevates circulating TMAO levels, which may reduce eNOS-derived NO production by increasing vascular oxidative stress and inflammation, contributing to CKD-associated endothelial dysfunction and cardiovascular disease.
More Related Videos
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction

